©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Feb 24, 2019; 10(2): 38-51
Published online Feb 24, 2019. doi: 10.5306/wjco.v10.i2.38
Published online Feb 24, 2019. doi: 10.5306/wjco.v10.i2.38
Oligometastases in prostate cancer: Ablative treatment
Amalia Palacios-Eito, Amelia Béjar-Luque, Milagrosa Rodríguez-Liñán, Sonia García-Cabezas, Department of Radiation Oncology, Reina Sofia University Hospital, Cordoba 14004, Spain
Author contributions: All authors contributed to this manuscript.
Conflict-of-interest statement: The authors have no conflict of interest related to the manuscript.
Corresponding author: Sonia García-Cabezas, MD, PhD, Associate Professor, Department of Radiation Oncology, Reina Sofia University Hospital, Avda. Menéndez Pidal, s/n, Cordoba 14004, Spain. songar1@gmail.com
Telephone: +34-95-7011415 Fax: +34-95-7011414
Received: August 24, 2018
Peer-review started: August 24, 2018
First decision: October 16, 2018
Revised: October 30, 2018
Accepted: January 9, 2019
Article in press: January 10, 2019
Published online: February 24, 2019
Processing time: 182 Days and 7.7 Hours
Peer-review started: August 24, 2018
First decision: October 16, 2018
Revised: October 30, 2018
Accepted: January 9, 2019
Article in press: January 10, 2019
Published online: February 24, 2019
Processing time: 182 Days and 7.7 Hours
Core Tip
Core tip: The hypothesis that oligometastatic disease may be cured with local eradication therapies has led to the growing use in prostate cancer (PCa) of treatments targeted to metastasis, including stereotactic body radiation therapy (SBRT). Such therapy intends to complement, replace or delay the introduction of systemic therapy. The present review aims to compile the evidence from the main ongoing studies and results on SBRT in relation to oligometastatic PCa, and examines aspects where gaps in knowledge persist, e.g., optimum schemes, response assessment, and identification and diagnosis of oligometastatic patients.